ABSTRACT. Bioavailabilities of oral rumen-protected and non-protected formulations of sulfamethoxazole (SMX) were compared in ruminating calves, since in vitro degradation of SMX in ruminal fluid was confirmed. The coated with a gastric-acid-soluble polymer and uncoated formulations were administered to 3 calves through a catheter. Neither formulation could produce sufficient blood concentration of the drug, though the bioavailability of SMX for the coated formulation was higher than that for the uncoated formulation. It was suggested that the rumen-protected drug could improve the bioavailability by escaping from degradation in the rumen, but scarcely attain the effective levels in blood. -KEY WORDS: rumen protect, ruminating calf, sulfamethoxazole.
37°C, shaken 70 times/min for 1, 3, or 6 hr. After incubation, the samples were stored at 20°C until analysis by HPLC.
SMX concentration in the rumen fluid rapidly decreased and was reduced to about 15% of the initial concentration at 6 hr after the beginning of the incubation. No difference was found in ability of the rumen fluid to degrade SMX among the calves. On the other hand, no change was detected in TMP concentration during the incubation, so further comparative studies were made on pharmacokinetics of SMX between the two oral formulations.
The oral formulations were administered intra-ruminally using a catheter or intra-abomasally using a nipple-bucket [5] . At first, three calves were administered the coated formulation at a dose of 20 mg SMX/kg of body weight through the nipple-bucket. After 7 days of drug wash-out, they were given the uncoated formulation by the same method for the coated one. Catheter dosing of the two oral formulations was performed at the same dose and interval as the nipple-bucket dosing. To determine the AUC (iv) of SMX, SMX sodium (purity of 100%, Shinomin Soda ® , Shionogi Pharmaceutical Co., Ltd., Japan) dissolved in saline was injected into the jugular vein at a dose of 20 mg/ kg. The calves were fasted 16 hr before and 6 hr after each dosing.
For determination of plasma SMX concentrations, blood samples were obtained beforehand and at 0.5, 1, 2, 3, 4, 6, 8, and 10 hr after each dosing, and additionally at 12 and 24 hr for the catheter dosing. SMX concentrations in the samples were determined by the HPLC, and pharmacokinetic parameters, such as plasma peak concentration (Cmax), time to reach the peak (Tmax), area under the concentration-time curve (AUC), were calculated by the methods previously described [5] . Bioavailability for each oral dosing was calculated by dividing the mean AUC 0-10 after oral dosing by the mean AUC 0-10 after intravenous dosing of SMX sodium.
After the nipple-bucket dosing to the abomasum, sufficient bioavailabilities of SMX were obtained for both formulations, although absorption of SMX for the coated formulation was slower and the bioavailability was about In our previous pharmacokinetic study on oral sulfamethoxazole (SMX) and trimethoprim (TMP) combination in ruminating calves [5] , intra-ruminal administration produced a extremely lower bioavailabilities of both drugs than intra-abomasal administration, suggesting that the intra-ruminally administered drugs might suffer degradation in the rumen. The purposes of the present study were to confirm the degradability of SMX and TMP in the rumen in vitro and to evaluate a rumen protected formulation after oral administration in ruminating calves.
Three Holstein male calves were purchased at one week of age from farms near the institute, and kept by the methods previously described [5] so as to stimulate early development of ruminal functions without losing the ability of reflex closure of the esophageal groove. The calves were used for the experiments when they were 6 weeks old, and at this time the body weights of the animals ranged from 66 to 77 kg with a mean of 72 ± 6 kg.
SMX and TMP combination powder (Shinoral San ® , Shionogi Pharmaceutical Co., Ltd., Japan) containing 5 g of SMX and 1 g of TMP in 150 g of the powder was the objective drug in this study and designated as the uncoated formulation. To prepare a rumen-protected formulation, 16.7 g of SMX and 3.3 g of TMP were granulated with 30.0 g of Eudragit ® E (Rohm Pharma GmbH, Wieterstadt, Germany), a gastric-acid-soluble polymer, by the method of wet granulation procedure [6] , and the granules, about 2 mm in diameter, were used as a coated formulation. When administered orally, the drugs were expected to be eluted from the coated granule into gastric fluid, since the polymer dissolves at pH 5 or below.
To examine abilities of the rumen contents of the calves to degrade the drugs, rumen fluid was collected from each calf using a rumen catheter and sieved with two layers of gauze to remove large debris. Twenty ml of the fluid was poured into 4 polyethylene vials, to which the uncoated formulation was added at concentrations of 200 µg/ml and 40 µg/ml for SMX and TMP, respectively. Each tube was flushed out with CO 2 and sealed with a rubber cork with gas release valve [7] , and placed in a thermostatic shakingbath (Thomas Kagaku Co., Ltd., Japan), kept at 20% smaller than those for the uncoated formulation (Table  1 and Fig. 1 ). The dissolution time of the polymer in the abomasum might be responsible for the slower absorption of SMX for the coated formulation.
When administered through the catheter, Cmax for both formulations varied in the calves, and neither formulation could produce sufficient plasma concentration of the drug. After the catheter dosing, Tmax for the coated formulation was longer than the uncoated formulation, in agreement with the finding after the nipple-bucket dosing. Bioavailabilities after the catheter dosing of both formulations varied in the calves, and lower than those after the nipple-bucket dosing ( Table 1) . As shown in Fig. 1 , plasma SMX concentration for the uncoated formulation showed rapid decline after the Tmax of 2 hr and decreased to the detection limit of 0.1 µg/ ml by 24 hr, while for the coated formulation almost the same concentration as Cmax was detected up to 10 hr. In the calves, AUC 0-24 values after the catheter dosing of the coated formulation were 1.6 to 5.2 times higher than those of the uncoated formulation ( Table 1) , showing that after the catheter dosing of the coated formulation larger amount of SMX was transferred into the small intestine and absorbed.
In calves with developed ruminal function, poor availability of drugs administered orally was thought to be caused by degradation in the rumen [1] . Actually, some chemotherapeutic drugs, such as chloramphenicol [1, 2] and TMP [4] , were reported to be degraded by the rumen fluid in vitro. In the present study, SMX was found to be degraded in the rumen fluid in vitro, and this would explain the rapid decline of plasma SMX concentrations which attributed to the poor bioavailability of the uncoated formulation after the catheter dosing. Degradation rate of TMP in the rumen 80.9 ± 3.4 99.4 ± 7.6 20.7 ± 6.6 14.0 ± 5.5
Bioavailability (%) = AUC 0-10 for the oral formulations/AUC 0-10 for the injectable formulation × 100. a) Not calculated. fluid in vitro was reported to vary in animals with different feeding conditions [4] . The rumen fluid of the calves used in the present study might have less ability to degrade TMP.
In conclusion, oral administration of the coated drug with rumen-protect polymer could improve the bioavailability of the drug by escaping from degradation in the rumen. Based on MICs of the combination or SMX alone for susceptible bacteria [3] , however, intra-ruminal administration of the coated drug at the same dose as intra-abomasal administration could not produce efficient levels of drug in blood due to long transit time through the rumen. From a therapeutic point of view, therefore, oral administrations to ruminating calves of the rumen-protected formulations as well as undegradable drugs were seemed to be of less practical value.
